FSD Pharma (NASDAQ:HUGE – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Analyst Recommendations
This is a summary of recent recommendations and price targets for FSD Pharma and VYNE Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FSD Pharma | 0 | 0 | 0 | 0 | N/A |
| VYNE Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
VYNE Therapeutics has a consensus price target of $18.50, suggesting a potential upside of 236.36%. Given VYNE Therapeutics’ higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than FSD Pharma.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FSD Pharma | N/A | N/A | -$23.61 million | ($0.75) | -1.81 |
| VYNE Therapeutics | $480,000.00 | 37.47 | -$23.21 million | ($10.65) | -0.52 |
VYNE Therapeutics has higher revenue and earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
FSD Pharma has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Profitability
This table compares FSD Pharma and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FSD Pharma | N/A | -111.46% | -86.47% |
| VYNE Therapeutics | -8,417.59% | -84.52% | -69.31% |
Insider and Institutional Ownership
1.2% of FSD Pharma shares are owned by institutional investors. Comparatively, 11.0% of VYNE Therapeutics shares are owned by institutional investors. 8.5% of FSD Pharma shares are owned by insiders. Comparatively, 4.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
VYNE Therapeutics beats FSD Pharma on 9 of the 12 factors compared between the two stocks.
About FSD Pharma
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
